Clinical characteristics

All the patients of device group acquired quickly autonomous usage. No adverse event nor pain was reported.

Improvement of mucus clearance and symptoms were similar between groups. FEV1(L) improved by +0.15±0.10L (FEV1% +5±2%)

and FEV1/FVC increased from 52.5±2.4% to 58.0±12.8% in the device group but remained stable in the manual physiotherapy group.

CAT score improved in the device group only from 20.2±6.4 to 17.0±4.6.

Conclusions

These preliminary data suggest safety and additional benefits of Simeox airway clearance technology for COPD with severe

chronic bronchitis symptoms or bronchiectasis. There is a need in further randomised studies including more patients for a

longer follow-up.

All parameters

with 150±100 ml and 5.2±2.3%

CAT score Mean ± SD

Drainage improvement (N, %)

20.2±6.4

5 (100%)

17.0±4.6 17.2±5.4

4 (80%)

18.6±4.0

Baseline EOS**

Dyspnea improvement (N, %)

4 (80%) 4 (80%)

Fatigue improvement (N, %)

4 (80%) 4 (80%)

Autonomy in execution

5 (100%) 4 (80%)

Variables

Manual Physiotherapy group values (N=5)

SIMEOX group values (N=5)

Baseline EOS*

PFTs characteristics

FVC (L) 1.97±0.89 2.01±0.82 2.19±0.77 1.93±1.05 1.99±0.90

Baseline EOS**

FVC (%) 55.7±17.5 55.5±18.4 60.6±15.9 55.9±18.7 60.2±18.0

FEV1 (L) 1.14±0.59 1.12±0.44 1.27±0.54 1.16±0.77 1.12±0.66

FEV1 (%) 42.2±19.0 39.5±13.5 44.6±15.8 45.0±24.8 44.8±24.9

FEV1/FVC% 53.2±7.5 52.5±2.4 58.0±12.1 55.4±10.7 51.7±14.1

Variables Groupe values (N=10)

Manual Physiotherapy group values (N=5)

SIMEOX group values (N=5)

Baseline EOS*

* End of Study (EOS) : 2 sessions of 20 minutes per day, for 5 days ** End of Study (EOS) : 2 sessions of 20 minutes per day, intensity 50-75%, for 5 days

* End of Study (EOS) : 2 sessions of 20 minutes per day, for 5 days ** End of Study (EOS) : 2 sessions of 20 minutes per day, intensity 50-75%, for 5 days

FEV1 with 40±110 ml and 0.02±0.08%FEV1

in FVC; in FEV1, FEV1/FVC%

35